Androgens as Therapy for Prostate Cancer
Author Information
Author(s): Chuu Chih-Pin, Kokontis John M, Hiipakka Richard A, Fukuchi Junichi, Lin Hui-Ping, Lin Ching-Yu, Huo Chiech, Su Liang-Cheng
Primary Institution: Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli, Taiwan
Hypothesis
Manipulating androgen/AR signaling may be a potential therapy for AR-positive advanced prostate cancer.
Conclusion
Androgens can suppress the growth of AR-positive advanced prostate tumors, suggesting that intermittent androgen deprivation therapy may improve patient outcomes.
Supporting Evidence
- Intermittent Androgen Deprivation therapy improves quality of life and reduces toxicity.
- Shortening the period of androgen ablation therapy may protect patients from side effects.
- High dosages of testosterone cause greater growth inhibition of relapsed tumors.
- Patients with low free testosterone have more extensive disease.
Takeaway
This study shows that giving androgens to men with advanced prostate cancer can help slow down the cancer's growth and make them feel better.
Methodology
The study involved cell culture and xenograft studies using androgen receptor-positive castration-resistant human prostate cancer cells.
Potential Biases
Potential bias in the selection of studies and data interpretation.
Limitations
The study primarily focuses on specific cell lines and may not fully represent all prostate cancer cases.
Participant Demographics
The study involved male patients with advanced prostate cancer.
Statistical Information
P-Value
0.013
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website